...
首页> 外文期刊>Journal of clinical gastroenterology >Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome.
【24h】

Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome.

机译:患有和不患有肠易激综合征的排尿障碍排便患者的生物反馈治疗结果。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: The Rome II and III diagnostic criteria for dyssynergic defecation require the exclusion of irritable bowel syndrome (IBS). To prospectively study whether the presence of IBS affects the outcome of biofeedback therapy in dyssynergic defecation patients. METHODS: Consecutive patients with dyssynergic defecation underwent biofeedback therapy. Dyssynergic defecation was diagnosed based on symptoms, anorectal manometries, balloon expulsion tests, and colonic transit studies. The defecation dynamics and balloon expulsion time were evaluated at the end of the biofeedback therapy in all patients. IBS symptoms were graded before and 4 weeks after the biofeedback therapy using a 4-point Likert scale. Failure of the biofeedback therapy was defined as <50% improvement of constipation symptoms, which were evaluated using a 10 cm long visual analog scale before and 4 weeks after biofeedback therapy. RESULTS: Fifty patients completed the study. The biofeedback therapy was successful in 30 patients. Twenty-nine patients fulfilled the Rome II criteria for IBS. Patients with or without IBS demonstrated similar responses to the biofeedback therapy (16 of 29 vs. 14 of 21, P>0.05). The disappearance of IBS symptoms was observed more frequently in patients with an improved defecation index compared with those with no improvement (8 of 12 vs 4 of 17, P<0.05). A high pretreatment constipation symptom score, a high rectal sensory threshold, and a delayed colonic transit time were associated with a poor treatment outcome. CONCLUSIONS: The presence of IBS in dyssynergic defecation did not affect the outcome of biofeedback therapy. In addition, treating dyssynergic defecation patients with IBS by biofeedback therapy improved both constipation and IBS symptoms.
机译:目的:罗马第二和第三代排尿障碍的诊断标准要求排除肠易激综合症(IBS)。前瞻性研究IBS的存在是否会影响功能不全排便患者的生物反馈治疗效果。方法:连续性排尿障碍的患者接受了生物反馈治疗。根据症状,肛门直肠测压,球囊排泄试验和结肠转运研究诊断为排尿障碍。在所有患者中,在生物反馈治疗结束时评估排便动力学和气囊排出时间。使用4点李克特量表对生物反馈疗法之前和之后的4周对IBS症状进行分级。生物反馈治疗失败的定义为便秘症状改善<50%,这是在生物反馈治疗之前和之后4周使用10 cm长的视觉模拟量表评估的。结果:50名患者完成了研究。生物反馈疗法在30例患者中取得了成功。 29名患者符合IBS的Rome II标准。有或没有IBS的患者对生物反馈疗法表现出相似的反应(29例中的16例与21例中的14例,P> 0.05)。排便指数改善的患者与未改善的患者相比,IBS症状消失的频率更高(12例中的8例对17例中的4例,P <0.05)。治疗前便秘症状评分高,直肠感觉阈值高和结肠转移时间延迟与治疗效果差有关。结论:IBS存在于功能障碍性排便中并不影响生物反馈疗法的结果。此外,通过生物反馈疗法治疗IBS失能性排便患者可改善便秘和IBS症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号